Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Ex vivo gene therapy based on CD34 + hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90% of HSC activity in less than 10% of mobilized peripheral blood (mPB) CD34 + cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E 2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34 + CD38 − cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“Recent clinical trials for patients affected by primary immunodeficiencies, hemoglobinopathies, or inborn errors of metabolism have shown high levels of gene transfer into HSPCs, which were stably maintained in multiple hematopoietic lineages until the latest follow-up, reaching up to 9 years in the earliest trial (Ca…”
BackgroundTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 1×
“…carrying semi-random LV integrations would reduce the integration load 10-fold, thereby decreasing the chances of gain-of-function events due to insertional mutagenesis, which may originate from immortalized progenitor cells (Cavazzana-Calvo et al., 2010; Stein et al., 2010; Braun et al., 2014).”
BackgroundGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184 · cited 3×
“Introduction of the lentiviral vector (LV) platform has spurred applications of gene therapy based on the transplantation of ex-vivo-engineered, autologous hematopoietic stem and progenitor cells (HSPCs) (Naldini, 2015).”
BackgroundSelf-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Self-citationIsolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment
Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I., & Dick, J. E. (2011) · Science · doi:10.1126/science.1201219 · Cited by 919 · cited 3×
“Furthermore, we show that almost all long-term repopulation activity is captured within the CD34+CD38 fraction, while, in agreement with CB data (Notta et al., 2011), substantial numbers of HSCs are contained within the CD34+CD90– fraction of mPB, which would be discarded in the case of a…”
BackgroundGene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562 · cited 1×
“…carrying semi-random LV integrations would reduce the integration load 10-fold, thereby decreasing the chances of gain-of-function events due to insertional mutagenesis, which may originate from immortalized progenitor cells (Cavazzana-Calvo et al., 2010; Stein et al., 2010; Braun et al., 2014).”
BackgroundTargeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555 · cited 2×
“While employing 16,16dimethyl prostaglandin E2 (PGE2) as an anti-apoptotic agent in ex vivo HSC gene-editing protocols, we noted that it increased gene-targeting efficiency (Genovese et al., 2014).”
MethodSelf-citationSessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502 · cited 2×
“Recent clinical trials for patients affected by primary immunodeficiencies, hemoglobinopathies, or inborn errors of metabolism have shown high levels of gene transfer into HSPCs, which were stably maintained in multiple hematopoietic lineages until the latest follow-up, reaching up to 9 years in the earliest trial (Ca…”
BackgroundSelf-citationBiasco, L., Pellin, D., Scala, S., Dionisio, F., Basso-Ricci, L., Leonardelli, L., Scaramuzza, S., Baricordi, C., Ferrua, F., Cicalese, M. P., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.04.016 · Cited by 243
Self-citation
Cited by
A comprehensive single cell transcriptional landscape of human hematopoietic progenitors
Pellin, D., Loperfido, M., Baricordi, C., Wolock, S. L., Montepeloso, A., Weinberg, O. K., Biffi, A., Klein, A. M., & Biasco, L. (2019) · Nature Communications · doi:10.1038/s41467-019-10291-0 · Cited by 360
Betibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia
Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., Sauer, M. G., Thuret, I., Lal, A., Algeri, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113206 · Cited by 283
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Self-citationHematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome
Gentner, B., Tucci, F., Galimberti, S., Fumagalli, F., De Pellegrin, M., Silvani, P., Camesasca, C., Pontesilli, S., Darin, S., Ciotti, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106596 · Cited by 171
Self-citationGene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
Metadata
- Authors
- Zonari, E., Desantis, G., Petrillo, C., Boccalatte, F. E., Lidonnici, M. R., Kajaste-Rudnitski, A., Aiuti, A., Ferrari, G., Naldini, L., & Gentner, B.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 8
- Issue
- 4
- Pages
- 977-990
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W2596045028
- Cited by
- 152
- References
- 9
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. https://app.cochat.ai/papers/10.1016/j.stemcr.2017.02.010
- The paper
- Zonari, E., Desantis, G., Petrillo, C., Boccalatte, F. E., Lidonnici, M. R., Kajaste-Rudnitski, A., Aiuti, A., Ferrari, G., Naldini, L., & Gentner, B. (2017). Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2017.02.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.